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Abstract
Acute kidney injury (AKI), previously named acute renal failure, is characterized by
abrupt deterioration in renal function. The incidence of AKI has increased lately, both in
the hospital and community setting. It is estimated that more than 13 million people are
affected by AKI annually worldwide. Despite all the advances in the field, AKI still carries
a high mortality rate. In addition to mortality, AKI is an important risk factor for the
development of chronic kidney disease. In this chapter, various aspects of AKI will be
discussed including definition and staging, etiology, pathophysiology, clinical presenta-
tion, diagnosis, management, prognosis, and prevention.
Keywords: acute kidney injury, renal failure, nephrotoxicity, pathophysiology,
biomarkers, management, prognosis, prevention
1. Introduction
Acute kidney injury (AKI) is a major public health concern and is associated with high
morbidity, mortality, and healthcare costs. The incidence of AKI has increased lately, both in
the hospital and community setting. It is estimated that more than 13 million people are
affected by AKI annually with an incidence of 21.6% in adults and 33.7% in children during a
single hospital episode of care [1, 2]. Despite all the advances in the field, the mortality of AKI
remains very high estimated at 23.9% in adults and 13.8% in children [2]. In addition to the
high mortality (1.7 million per year), AKI is associated with high morbidity and high costs [1].
In the United States, at least $5 billion in hospital costs are related to AKI, while in England
AKI consumes 1% of the National Health Service budget [3]. In the developed world, AKI
manifests mainly in older patients and in the intensive care settings; while in the developing
countries, adults and women are particularly more commonly affected [4, 5]. Recovery from
AKI is not always, as previously thought, complete and many patients progress to develop
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chronic kidney disease (CKD), end-stage renal disease (ESRD), or worsening of preexisting CKD
later on in life [6–9]. Treatment of AKI is needed to reduce the high morbidity and mortality and
improve recovery of renal function. A part of dialysis, there are no other interventions that
reliably improve survival, limit injury, or enhance recovery. The multifactorial etiology and the
heterogeneous patient population coupled with the complicated clinical course of patients with
AKI has created challenges in the search for effective pharmacological therapy [10]. In some
scenarios, such as surgery or administration of intravenous contrast, the onset of AKI can be
predicted providing a window of opportunity for intervention and prevention. In the majority of
cases, however, intervention takes place after the onset of AKI with the aim to shorten the course
and enhance recovery of renal function. In this chapter, various aspects of AKI will be discussed
with a particular focus on definition and staging, etiology, pathophysiology, clinical presentation,
diagnosis, management, prognosis, and prevention.
2. Definition and staging of acute kidney injury
The term AKI has replaced old terms such as acute renal failure and acute renal insufficiency,
which previously had been used to describe the same clinical condition. AKI is not just failure;
it also incorporates the entire spectrum of the syndrome, from minor changes in renal function
to the most severe form, where renal replacement therapy (RRT) may be required.
Over the last few decades, more than 35 different definitions have been used to define AKI
[11]. The most commonly used definition is based on urine output and/or serum creatinine
criteria. The most commonly used classifications of AKI are the “risk, injury, failure, loss of
kidney function, and end-stage kidney disease” (RIFLE) [12] and the Acute Kidney Injury
Network (AKIN) classifications [13].
The RIFLE classification is based on serum creatinine and urine output determinants, and
considers three severity classes of AKI (risk, injury and failure), according to the variations in
serum creatinine and or urine output, and two outcome classes (loss of kidney function and
end-stage kidney disease). The patient should be classified using the criteria which leads to the
Class GFR Urine output
Risk ↑ SCr  1.5 or ↓ GFR >25% <0.5 mL/kg/h  6 h
Injury ↑ SCr  2 or ↓ GFR >50% <0.5 mL/kg/h  12 h
Failure ↑ SCr  3 or ↓ GFR >75% or if baseline SCr ≥353.6 μmol/L (≥4 mg/dL) ↑
SCr >44.2 μmol/L (>0.5 mg/dL)
<0.3 mL/kg/h  24 h or
anuria  12 h
Loss of kidney
function
Complete loss of kidney function >4 weeks
End-stage kidney
disease
Complete loss of kidney function >3 months
GFR, glomerular filtration rate; SCr, serum creatinine.
Table 1. Risk, injury, failure, loss of kidney function and end-stage kidney disease (RIFLE) classification of acute kidney
injury [12].
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worst classification (maximum RIFLE), Table 1. On the other hand, AKI is classified/staged by
the AKIN into three stages as shown in Table 2.
The Kidney Disease Improving Global Outcomes (KDIGO) work group has combined the RIFLE
and AKIN classifications in order to establish one classification of AKI for practice, research and
public health. Therefore, AKI is now defined as an abrupt reduction in renal function (within
48 h) based on an increase in serum creatinine level of more than or equal to 0.3 mg/dL
(≥26.4 μmol/L), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold
from baseline), or a reduction in urine output (documented oliguria of less than 0.5 mL/kg/h for
more than 6 h) or a combination of these factors [14].
3. Etiology of acute kidney injury
The etiology of AKI can be divided into three categories, Table 3 [15]:
1. Prerenal (caused by decreased renal perfusion, often due to volume depletion)
2. Intrinsic renal (caused by a process within the kidneys)
3. Postrenal (caused by a process distal to the kidneys such as obstruction)
Stage Change in serum creatinine Urine output
1 Increase ≥0.3 mg/dL (26.52 μmol/L) or ≥150–200% from baseline <0.5 mL/kg/h for more than
6 h
2 Increase >200–300% from baseline <0.5 mL/kg/h for more than
12 h
3 Increase >300% from baseline or ≥4.0 mg/dL (353.60 μmol/L) with an acute rise of at
least 0.5 mg/dL (44.20 μmol/L)
<0.3 mL/kg/h for 24 h or
anuria for 12 h
Table 2. Acute Kidney Injury Network (AKIN) classifications of acute kidney injury [13].
Prerenal
Intrarenal vasoconstriction (hemodynamically mediated):
Medications: nonsteroidal anti-inflammatory drugs, angiotensin system blockers, calcineurin inhibitors
Cardiorenal syndrome: advanced heart failure
Hepatorenal syndrome: liver cirrhosis
Abdominal compartment syndrome
Hypercalcemia
Systemic vasodilation: sepsis
Volume depletion:
Renal loss: diuretics, osmotic diuresis (severe hyperglycemia), salt wasting
Extrarenal loss: blood loss, gastrointestinal loss (vomiting, diarrhea), skin (burns, sweating)
Acute Kidney Injury
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Of these three categories, only “intrinsic” AKI represents a true kidney disease, while pre- and
postrenal AKI are the consequence of extrarenal processes that lead to decreased glomerular
filtration rate (GFR). Both pre- and postrenal conditions, if persist and not managed in a timely
manner, may eventually evolve into intrinsic renal damage. Patients with CKD and those
admitted to the intensive care unit (ICU) are particularly prone to develop AKI. The AKI-EPI
study demonstrated that AKI occurred in more than half of the patients in ICU; mostly due to
sepsis and hypovolemia followed by nephrotoxic agents [16].
4. Pathophysiology of acute kidney injury
Despite the identification of several cellular mechanisms thought to underlie the development
of AKI, the pathophysiology of AKI is still poorly understood. Animal models of AKI
representing ischemia–reperfusion injury and drug nephrotoxicity have been instrumental in
understanding the pathophysiology of AKI in humans. Although the current in vivo models of
AKI in healthy rodents provide valuable information about the pathophysiological mecha-
nisms of renal injury, they do not reflect the complexity of disease in humans characterized by
Intrinsic renal
Glomerulonephritis (isolated or a part of systemic diseases)
Interstitial nephritis:
Medications: antibiotics (β lactams, sulfonamides, quinolones, rifampin), phenytoin, antiretrovirals, proton pump
inhibitors, nonsteroidal anti-inflammatory drugs
Infections: viruses (Epstein-Barr virus, cytomegalovirus, human immunodeficiency virus), bacteria (tuberculosis,
legionella species), fungi (candidiasis, histoplasmosis)
Systemic disease: sarcoidosis, connective tissue diseases
Tubular necrosis:
Ischemic: prolonged hypotension
Nephrotoxic: exogenous toxins (radiographic contrast agents, aminoglycosides, cisplatin, methotrexate,
amphotericin B)
Endogenous toxins: pigment induced (hemolysis and rhabdomyolysis), tumor lysis syndrome, multiple myeloma
Vascular
Renal artery and vein thrombosis, malignant hypertension, scleroderma renal crisis, atheroembolic disease,
microangiopathies
Post renal
Extrarenal obstruction: outlet obstruction (prostate hypertrophy, neurogenic bladder; malignancy of the urogenital tract),
retroperitoneal fibrosis
Intrarenal obstruction: stones, crystals (acyclovir, indinavir, ethylene glycol), blood clots, tumors
Adapted and modified from Rahman et al. [15].
Table 3. Etiology of acute kidney injury.
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population’s heterogeneity and preexisting comorbidities such as diabetes, hypertension, and
CKD. A few and not all mechanisms of AKI will be discussed.
4.1. Microvascular injury
The renal microvasculature plays a key role in the pathophysiology of AKI. The kidney is a
vascular organ receiving 25% of the cardiac output and has a high energy demand with rela-
tively low oxygen (O2) extraction. Under normal steady-state, the O2 supply to the kidney is well
regulated. Adequate O2 delivery is crucial for the production of mitochondrial adenosine tri-
phosphate (ATP), nitric oxide (NO), and reactive oxygen species (ROS) necessary for homeostatic
control of renal function [10, 17]. The vascular architecture of the outer medulla is particularly
susceptible to ischemic injury due to the marginal oxygenation of this part of the kidney.
With injury, the microcirculation is compromised leading to an imbalance in NO, ROS, and O2
supply and consumption. Subsequent pathogenic events follow including hypoxia and oxida-
tive stress. Injury to the microvascular endothelium and changes in the glycocalyx lead to
endothelial cell activation and expression of cell surface markers that promote recruitment
and adhesion of leukocytes and platelets, leading to further changes in perfusion and O2
delivery; and to additional endothelial cell injury and inflammation [18, 19]. As a result,
increased vascular permeability and development of interstitial edema lead to further compro-
mise of blood flow exacerbating the initial insult. In addition, production of vasoactive prosta-
glandins by damaged tubular cells coupled with oxidative stress further impairs O2 delivery
by worsening the local microvascular occlusion [18, 19]. The main long-term result of micro-
vascular injury is a reduction in peritubular capillary density, a response to decreased vascular
endothelial growth factor (VEGF) and increased transforming growth factor beta (TGF-β)
signaling, which contributes to ongoing hypoxia and development of renal fibrosis [20].
4.2. Changes in endoplasmic reticulum
The endoplasmic reticulum (ER) plays an important role in the maintenance of protein homeo-
stasis through its control of the concentration, conformation, folding, and trafficking of client
proteins. As a result of endothelial or epithelial cell stress, unfolded or misfolded proteins
accumulate in the ER, triggering the unfolded protein response (UPR) [21]. The UPR initially
serves as an adaptive response, but will also induce apoptosis in cells under severe or
prolonged ER stress. Accumulating evidence indicates that apoptosis in tubules resulting from
epithelial cell damage is caused, at least in part, by the proapoptotic UPR [22]. Therefore,
targeting the UPR may present a possible approach to prevent or treat AKI.
4.3. Mitochondrial dysfunction
The ER and mitochondria have multiple contact sites termed the mitochondrial-ER-associated
membrane (MAM). The MAM contains proteins from the two organelles and appears as ER
tubules closely apposed to the mitochondria on electron micrographs [23]. During cellular
stress situations, like an altered cellular redox state, the MAM alters its set of regulatory
proteins and thus alters MAM functions. In the pathogenesis of AKI, proximal tubules are
Acute Kidney Injury
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especially vulnerable to mitochondrial dysfunction as they depend on aerobic metabolism and
their mitochondria are in a more oxidized state than those in the distal tubular cells which can
use glycolysis [24]. Following either ATP depletion or cisplatin treatment of rat renal tubular
cells, mitochondrial fragmentation was observed prior to cytochrome c release and apoptosis
[25]. Targeting mitochondrial dysfunction along with a better understanding of the regulation
of mitochondrial dynamics and its pathogenic changes may emerge as a new modality to treat
AKI [26].
4.4. Autophagy
Autophagy is a catabolic process in which proteins, organelles, and cytoplasmic components
are delivered to lysosomes for degradation and recycling. Autophagy is induced in renal
tubular cells during AKI [27]. It is initiated by encapsulating cytoplasmic proteins and organ-
elles in autophagosomes, which fuse with lysosomes for degradation. Once activated, it may
decrease cellular stress by removing ER membranes containing UPR sensors and/or clearing
abnormal proteins from the ER. In animal models, blocking the autophagic flux-enhanced
AKI, while activation of autophagy was found to be protective against cisplatin-induced AKI
[27]. In addition, resolution of autophagy may promote proliferation and regeneration of
tubular cells in the recovery phase of AKI [28]. Autophagy may be targeted as an inflamma-
tory modulator for the treatment of various kidney diseases [29].
4.5. Inflammation
Inflammation plays a major role in the pathophysiology of AKI resulting from ischemia [30].
Changes in protein folding and mitochondrial function influence the innate immune response,
contributing to inflammation. In addition, several cytokines and inflammatory pathways are
activated in AKI [30]. Moreover, immune cells of both the innate and adaptive immune
systems, such as neutrophils, dendritic cells, macrophages, and lymphocytes, contribute to
the pathogenesis of renal injury after ischemia–reperfusion injury, and some cells also partici-
pate in the repair process [31]. Neutrophils and monocytes mediate the acute phase within the
first 24 h of injury [32], whereas T and B lymphocytes are important in the evolution phase of
renal injury [31]. Inhibition of leukocyte infiltration into the kidney ameliorates the loss in renal
function, decreases renal injury, cell death, and long-term fibrosis [33]. There is experimental
evidence that inducible nitric oxide synthase (iNOS) may contribute to tubular injury during
AKI [34]. It has been shown that hypoxia in isolated proximal tubules increases nitric oxide
release [35], and that iNOS protein expression is increased in ischemic kidneys [36]. In vivo use
of an antisense oligonucleotide to block the up-regulation of iNOS was protective against
ischemia induced renal injury in rat models [36]. Similarly, tubules from iNOS knockout mice
were protected against hypoxic injury [37].
Phospholipase A2 (PLA2) is a family of enzymes that hydrolyzes the acyl group from the sn-2
position of phospholipids, generating free fatty acids [38, 39]. PLA2 activity is increased during
hypoxic injury to the renal tubules. Inhibiting PLA2 by exogenous fatty acids such as
arachidonic acid has been shown to be protective against hypoxia-induced injury in isolated
proximal renal tubules [40, 41].
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4.6. Sepsis and acute kidney injury
Sepsis is a severe inflammatory response to infection characterized by a whole-body inflam-
matory state with severe consequences, including multiple organ failure [42]. AKI is a frequent
and serious complication of sepsis among ICU patients and is associated with a high in-
hospital and long-term mortality [43, 44]. The multinational AKI-EPI study has demonstrated
that AKI affected more than 50% of ICU patients, and increasing AKI severity was associated
with increased mortality [16].
4.6.1. Pathogenesis of sepsis-induced acute kidney injury
Although septic shock is a leading cause of AKI, the underlying mechanisms are not
completely understood. The pathophysiology of AKI in sepsis is complex and multifactorial
involving multiple processes including intrarenal hemodynamic perturbations, endothelial
dysfunction, infiltration of inflammatory cells, up-regulation of inflammatory cytokines,
intraglomerular thrombosis, induction of apoptosis, and tubular obstruction with necrotic
cells and debris [42, 45, 46]. Activation of pro- and anti-inflammatory mechanisms is
believed to play a key role in the induction of sepsis [47].
Activation of the innate immune response takes place after initial host-microbial encoun-
ter, which coordinates a defensive response involving both humoral and cellular compo-
nents [48]. This leads to activation and secretion of various cytokines, most importantly
interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and IL-6 that progress to a state of
cytokine storm, hemodynamic instability, and eventually organ dysfunction and septic
shock [42].
Lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria, is
a potent and rapid activator of a variety of cell types such as leukocytes, monocytes, and
macrophages [49]. Activation of inflammatory cells by LPS constitutes the first step in a
cascade of events that lead to the manifestation of Gram-negative sepsis. LPS initiates
multiple intracellular signaling events, including the activation of nuclear factor-κB (NF-κB),
which ultimately leads to the synthesis and release of a number of pro-inflammatory medi-
ators, including IL-1, IL-6,IL-8, and TNF-a. The pathway that leads to activation of NF-κB
has been shown to be mediated by members of the toll-like receptors (TLRs), a family of
transmembrane proteins that play an important role in the defense against pathogenic
microbial infection [50]. In the setting of sepsis, there is a significant up-regulation of TLRs,
in particular TLR-2 and TLR-4 expression [51]. Both TLR-2 and TLR-4 are activated by LPS in
a response that depends on LPS-binding protein and is enhanced by CD14 [49, 52]. An
overview of the TLR signaling pathway is depicted in Figure 1 [53]. Figure 2 depicts the
key pathways involved in the clinical course of sepsis that also have implications in the
pathophysiology of sepsis-induced AKI [42].
Modulation of TLRs may become a novel therapeutic target in the treatment of organ dysfunc-
tion associated with sepsis including AKI. Similarly, cytokine adsorption to the membrane
during continuous renal replacement therapy may emerge as a treatment modality in patients
with sepsis and AKI [54].
Acute Kidney Injury
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Figure 1. Toll-like receptor (TLR) signaling pathway. When TLRs are stimulated by their respective ligands, they
dimerize and recruit downstream adaptor molecules, such as myeloid differentiation primary-response protein 88
(MyD88), MyD88-adaptor-like (MAL), toll/interleukin (IL)-1 receptor (TIR)-domain-containing adaptor-inducing
interferon-β (TRIF), TRIF-related adaptor molecule (TRAM), which activate other downstream molecules leading to
the activation of signaling cascades that converge at the nuclear factor-κB (NF-κB), interferon (IFN) response factors
(IRFs), and mitogen-activated protein (MAP) kinases. These molecules induce the transcription of several pro-
inflammatory molecules, such as interleukin (IL)-6, IL-8, IL-12, and tumor necrosis factor-α (TNF-α). AP1, activator
protein 1; ATF, activating transcription factor; dsRNA, double-stranded RNA; ERK, extracellular signal-regulated
kinase; IKK, inhibitor of kappa light polypeptide gene enhancer in B-cell kinase; IRAK, IL-1 receptor-associated
kinase; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MD, myeloid differentiation factor; MKK, MAPK
kinase; NA, nucleic acid; TAB, transforming growth factor-β-activated kinase 1/MAP3K7-binding protein; TAK,
transforming growth factor-activated kinase; TRAF, tumor necrosis factor receptor-associated factor; RIP1, receptor-
interacting protein 1. Adapted from Anwar et al. [53].
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5. Clinical presentation of acute kidney injury
The clinical presentation of AKI depends on the cause and severity of renal insult. Mild
to moderate AKI is asymptomatic and patients are identified based on laboratory testing.
However, patients with severe AKI often present with a variety of symptoms including
fatigue, anorexia, nausea, vomiting, restlessness, confusion, fluid retention, and weight
gain. Severe and prolonged AKI may cause central nervous system manifestations such
as uremic encephalopathy with asterixis, confusion, and seizure; bleeding tendency due
to platelet dysfunction and severe anemia. Patients with AKI may have normal urine
output, oliguria (urine output less than 400 mL/24 h) or anuria (urine output less than
100 mL/24 h).
Figure 2. Key pathogenic pathways involved in sepsis that also have implications in the pathophysiology of sepsis-
induced acute kidney injury. Adapted from Zarjou and Agarwal [42].
Acute Kidney Injury
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6. Diagnosis of acute kidney injury
History and physical examination, with an emphasis on assessing the patient’s volume status,
are crucial for determining the cause of AKI. The history should inquire about the use of nephr-
otoxic medications or presence of systemic illnesses that might impair renal perfusion or directly
impair renal function. Physical examination should assess the intravascular volume status and
any skin rashes that indicate systemic diseases. The initial laboratory evaluation should include
urinalysis, urine microscopy, complete blood count, electrolytes, serum creatinine or cystatin C
level, and fractional excretion of sodium (FENa). Urinalysis and urine microscopy are essential in
the initial work up of AKI. Findings on urinalysis and urine microscopy guide the differential
diagnosis and direct further investigation. Imaging studies in particular ultrasonography can
help in the initial work up of AKI. Ultrasonography is particularly important in older men with
AKI who may have bladder outlet obstruction as a result of prostate hypertrophy [55, 56]. Renal
biopsy is reserved for patients with AKI where the cause is not clear. Renal biopsy is particularly
important when there is suspicion of an underlying disease that requires specific therapy such as
glomerulonephritis or interstitial nephritis. Renal biopsy should be performed urgently in cases
of rapidly progressive glomerulonephritis as indicated by rising serum creatinine or cystatin C
and presence of red blood cell casts or dysmorphic red blood cells on urine microscopy.
7. New biomarkers for the quick detection of acute kidney injury
Although the RIFLE and AKIN criteria, based on serum creatinine and urine output, were a
step forward in diagnosing AKI, a reliable tool to differentiate between true parenchymal
and prerenal azotemia in clinical practice is still lacking [57]. Lately, several papers on the
use of new urinary and serum biomarkers for the diagnosis and prognostication of AKI have
been published with the hope that these biomarkers will lead to a new era of earlier diagno-
sis, better prognostication and treatment. Some of the studied biomarkers are listed in
Table 4. Although these biomarkers may help to understand some of the biochemical and
biological processes during AKI, their utility in preventing and treating AKI at present is at
most very limited [58].
Acronym Legend Main source
AP Alkaline phosphatase Liver, bone, intestine, placenta, brush border proximal convoluted tubules
α1MG Alpha 1 microglobulin Liver. Reabsorption by renal proximal tubular cells
α1acidGP Alpha 1 acid glycoprotein Liver. Reabsorption by renal proximal tubular cells
Β2MG Beta 2 microglobulin All nucleated cells. Reabsorption by renal proximal tubular cells
Cystatin C Cystatin C All nucleated cells. Reabsorption by renal proximal tubular cells
FENA Fractional excretion of
sodium
GGTP Gamma glutamyl
transpeptidase
All cells except myocytes. Mainly liver and kidney (brush border proximal
convoluted tubules and loop of Henle)
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8. Management of acute kidney injury
Management of AKI mandates close collaboration among nephrologists and other physicians
involved in the care of the patient. The clinical evaluation of AKI includes a careful history and
thorough physical examination. Drug history should include over-the-counter medications,
herbal remedies, and recreational drugs [59]. Once established, management of AKI is mainly
Acronym Legend Main source
αGST Alpha-glutathione S-
transferase
Expressed in almost all tissues. Kidney: proximal tubular cells
(cytoplasmatic)
piGST Pi glutathione S-transferase Expressed in almost all tissues. Kidney: distal tubular cells (cytoplasmatic)
HGF Hepatocyte growth factor Mesenchymal cells
IL-6 Interleukin 6 T lymphocytes, macrophages, endothelial cells, monocytes
IL-8 Interleukin 8 Monocytes, macrophages, epithelial cells, endothelial cells
IL-10 Interleukin 10 Monocytes, lymphocytes, macrophages
IL-18 Interleukin 18 Monocytes, dendritic cells, macrophages and epithelial cells
KIM-1 Kidney injury molecule 1 Kidney: proximal tubular cells
LFABP Liver-type fatty acid-binding
protein
Hepatocytes, kidney: proximal tubular cells
NGAL Neutrophil gelatinase-
associated lipocalin
Leucocytes, loop of Henle and collecting ducts
NAG N-Acetyl beta
glucosaminidase
Several tissues (liver, brain, spleen, etc.). Kidney: proximal tubular cells
(lysosomal)
PAI-1 Plasminogen activator
inhibitor 1
Endothelium
PCX Podocalyxin Podocytes
RBP Retinol-binding protein Liver. Reabsorption by renal proximal tubular cells
sTNFR-I Soluble tumor necrosis factor
receptor I
Most cells and tissues (cytotoxic, apoptotic, and pro-inflammatory effects)
sTNFR-II Soluble tumor necrosis factor
receptor II
Most cells and tissues (proliferative and anti-apoptotic effects)
TNF-α Tumor necrosis factor alpha Macrophages, lymphoid cells, renal parenchymal cells
11 k-TXB2 11-keto-Thromboxane B2 Platelets
vWF Von Willebrand factor Endothelium, megakaryocytes, subendothelial connective tissue
TIMP-2 Tissue inhibitor of
metalloproteinase-2
Ubiquitous expression. Renal tubular cells
IGFBP7 Insulin-like growth factor-
binding protein 7
Ubiquitous expression. Renal tubular cells
Adapted and modified from Vanmassenhove [57].
Table 4. Urinary and serum biomarkers for the diagnosis of acute kidney injury.
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supportive. Most patients with AKI should be hospitalized unless the condition is mild and
attributed to an easily reversible cause. The evaluation and initial management of patients with
AKI should include: (1) an assessment of the contributing causes of the kidney injury, (2) an
assessment of the clinical course including comorbidities, (3) a careful assessment of volume
status, and (4) the institution of appropriate therapeutic measures designed to reverse or
prevent worsening of functional or structural kidney abnormalities [60]. The initial assessment
of patients with AKI should include the differentiation between prerenal, renal, and postrenal
causes [34, 61–63]. In the majority of cases, the exclusion of postrenal causes using ultrasonog-
raphy is an established approach and sufficient for the initial assessment. Differentiation
between prerenal and renal causes is more challenging as renal hypoperfusion may coexist
with any stage of AKI.
Assuring adequate renal perfusion by achieving and maintaining hemodynamic stability and
avoiding hypovolemia is crucial in the initial management of AKI. Measurement of central
venous pressures may be helpful in case of difficulty in assessing intravascular volume.
Prerenal azotemia is rapidly reversible when the underlying cause is corrected [34, 60–63]. It
is important to point out that certain elements of the definition of prerenal azotemia have
diagnostic limitations. In the setting of renal hypoperfusion, compensatory mechanisms aimed
at maintaining GFR may become operative. These compensatory mechanisms include efferent
arteriolar vasoconstriction, afferent arteriolar dilation, and neuro/hormonal changes that lead
to increased tubular reabsorption of solutes and water [64]. This implies that patients with
renal hypoperfusion may be classified as having AKI by urine output criteria without having a
significant change in serum creatinine concentration.
Volume resuscitation can correct prerenal conditions resulting from absolute or relative
hypovolemia. However, renal hypoperfusion resulting from low cardiac output (severe car-
diomyopathy) and reduced renal perfusion pressure (sepsis, or end-stage liver disease) cannot
always be corrected by fluid administration [60]. Isotonic solutions (e.g., 0.9 sodium chloride)
are preferred over hyperoncotic solutions due to the detrimental effect of these solutions (e.g.,
dextrans, hydroxyethyl starch, and albumin) [65, 66]. The use of hydroxyethyl starch as a
plasma-volume expander has been shown to be an independent risk factor for AKI in patients
with severe sepsis or septic shock [65]. In patients with persistent hypotension, vasopressors
may be needed to maintain a mean blood pressure of 65 mmHg [66].
9. Pharmacologic interventions for management of acute kidney injury
A number of pharmacologic interventions have been evaluated in the early management of AKI.
Some have been designed to improve renal perfusion and others to modulate intrarenal patho-
physiology. In patients with hyperdynamic septic shock, both norepinephrine and terlipressin
were effective in raising mean arterial blood pressure (MAP) leading to an improvement in renal
function [67].
Low-dose (renal-dose) dopamine was frequently used in the ICU setting for its presumed
renoprotective effects. Low-dose dopamine may increase the urine output on the first day of
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use, but prospective and retrospective studies as well as several meta-analyses have not
shown positive effect in prevention of AKI or improvement in renal function in patients with
AKI [68–71]. To the contrary, low-dose dopamine has been shown to worsen renal perfusion
in patients with established AKI [72]. Therefore, the routine use of low-dose dopamine in
critically ill patients should be abandoned.
Randomized controlled trials of early AKI and contrast nephropathy studying fenoldopam, a
selective dopamine A1 agonist, proved this agent is ineffective at protecting renal function or
reducing the need for renal replacement [73, 74]. Fenoldopam has been shown, however, to
lower the risk of AKI in cardiac and major surgery patients according to some meta-analyses,
without an effect on renal replacement or hospital mortality [75, 76]. In most of these studies,
fenoldopam was associated with hypotension.
High-chloride fluids may be associated with increased risk of AKI and mortality in patients
with sepsis [77]. Early goal-directed therapy with close monitoring of central venous pressure,
mean arterial pressure, and oxygen saturation has been shown to be protective against AKI in
patients admitted to the intensive care unit with sepsis [78, 79].
Atrial natriuretic peptide (ANP) is produced by cardiac atrial myocytes in response to atrial
distension or increased atrial pressure. It induces afferent dilatation and efferent vasoconstriction,
thereby increasing glomerular filtration and urinary sodium excretion [80]. B-type (brain) natri-
uretic peptide (BNP) is primarily produced in the cardiac ventricles and has similar effects [81, 82].
Low doses of recombinant human ANP-enhanced renal excretory function, decreased the proba-
bility of dialysis, and improved dialysis-free survival in early, ischemic acute renal dysfunction
after complicated cardiac surgery [83]. Similar effects were observed in patients undergoing liver
transplantation [84, 85]. However, larger doses of ANP were not effective in improving dialysis-
free survival or reduction in dialysis in large randomized clinical trials [86, 87].
Theophylline, an adenosine antagonist has been shown in several preliminary reports to be
beneficial in the prevention of contrast nephropathy and cisplatin nephrotoxicity [88–90]. A
few adjunctive agents such as flavonoids (silymarin) and carotenoids (lycopene), have been
tried in pilot studies in cancer patients receiving cisplatin with limited success in some but not
all studies [91–93]. Adequately powered, controlled studies to support the efficacy of these
agents are lacking.
Levosimendan, a calcium sensitizer, has inodilator, cardioprotective, and anti-inflammatory
effects [94]. Two meta-analyses suggested that the use of levosimendan was associated with a
reduction of renal replacement therapy in critically ill patients and patients undergoing cardiac
surgery [95, 96]. The studies in both meta-analyses were small, heterogeneous, and AKI was
not always a predefined endpoint.
The role of loop diuretics and osmotic agents in the prevention and treatment of AKI in
humans has been disappointing despite their ability to decrease the tubular oxygen consump-
tion and relieve intratubular obstruction in animal models [97–99]. A metanalysis has shown
that frusemide was not associated with any significant clinical benefits in the prevention and
treatment of AKI in adults, in addition to the concern of increased risk of ototoxicity associated
with high doses [100].
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N-acetyl-cysteine, a thiol-containing antioxidant has been investigated in several trials, mainly in
the prevention of contrast-induced nephropathy. Despite some positive reports [101, 102], the
protective effect of N-acetyl-cysteine is still controversial [103–106]. Similarly, N-acetyl-cysteine
was not found to be protective against other causes of AKI particularly in hypotensive patients in
the ICU or patients undergoing cardiac surgery [107, 108]. Hydration with sodium bicarbonate,
as compared to normal saline, has been shown in some studies to be superior to normal saline in
the prevention of contrast-induced nephropathy [109–111]. Other studies have shown no supe-
riority of sodium bicarbonate over saline in the prevention of contrast nephropathy [112, 113].
Hydration with isotonic solutions either normal saline or sodium bicarbonate in addition to the
use of low osmolar contrast agents is the most effective strategy to prevent contrast-induced
nephropathy.
Statins may have a beneficial effect in high-risk patients exposed to contrast administration for
angiography. In a randomized multicenter clinical trial, the short-term use of rosuvastatin was
found to be protective against contrast nephropathy in diabetic patients with concomitant
CKD who underwent coronary/peripheral arterial angiography [114]. In another single center
trial high-dose rosuvastatin (40 mg on admission followed by 20 mg daily) given to statin-
naïve patients with acute coronary syndrome who were scheduled for an early invasive
procedure was protective against contrast-induced AKI and improved the short-term clinical
outcome [115]. 6.7% of patients in the early high-dose rosuvastatin group developed AKI
compared to 15.1% in the control group. The 30-day rate of adverse cardiovascular and renal
events was also reduced in the rosuvastatin group (3.6 versus 7.9%). In a subgroup analysis of
this study, rosuvastatin had a protective effect among female diabetic patients with CKD [116].
Similarly, a single high dose of atorvastatin (80 mg) administered within 24 h before exposure
to intravenous contrast was effective in reducing the rate of AKI in diabetic patients with renal
dysfunction [117, 118]. The protective effect of statins has been confirmed in multiple meta-
analyses [119–121]. However, the beneficial effect of statins in patients undergoing coronary
interventions was not observed in patients undergoing cardiac surgery. In this group of
patients, the use of statin either showed no benefit or was detrimental [122–124].
10. Renal replacement therapy for acute kidney injury
There is a wide variation in clinical practice relating to the indication for and timing of RRT for
patients with AKI. There is also no agreement on the selection of the specific modality of RRT
and prescription of intensity of therapy. Among the several modalities of RRT, continuous
renal replacement therapy has become very popular, especially in the ICU setting where
patients may be hemodynamically unstable to tolerate intermittent hemodialysis. There does
not appear to be a significant difference in either mortality or recovery of renal function
associated with the various modalities of RRT. This is discussed in details in other sections of
the book designated for RRT.
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11. Prevention of acute kidney injury
Acute kidney injury is particularly common in ICU patients affecting more than 50% and is
associated with increased mortality and morbidity [16]. The Working Group on Prevention, AKI
section, European Society of Intensive Care Medicine has recently issued recommendations for
the prevention of AKI, specifically addressing the role of fluids, diuretics, inotropes, vasopres-
sors/vasodilators, hormonal and nutritional interventions, sedatives, statins, remote ischemic
preconditioning, and care bundles as shown in Table 5 [125]. The recommendations are summa-
rized as follows: timely resuscitation with fluids, vasopressors, and inotropic agents remains the
cornerstone in the prevention of AKI. Volume expansion with isotonic crystalloids is reserved for
true and suspected hypovolemia. The use of starches and dextrans should be avoided. In
hypotensive patients, vasoconstrictors, preferably norepinephrine, should be administered with
or following volume expansion. Mean arterial pressure (MAP) of 65–70 mmHg is adequate in
most patients except in cases of preexisting chronic hypertension where a higher MAP (80–
85 mmHg) should be targeted. Review of all medications and cessation of nephrotoxic agents is
mandatory. Diuretics should not be used for prevention of AKI but may benefit in cases of
volume overload and congestion. Hyperglycemia should be avoided. The effect of statins
appears to depend on the setting, with promising results in contrast administration but no effect
or even harm in cardiac surgery patients [125].
Volume expansion
Controlled fluid resuscitation in volume depletion, while, however, avoiding volume overload (1 C)
Avoidance of starches, gelatine, and dextrans (2C)
Correction of hypovolemia/dehydration using isotonic crystalloids in patients receiving intravascular contrast media (1 B)
Regular monitoring of chloride levels and acid–base status in situations where chloride-rich solutions are used (BPS)
Use of balanced crystalloids for large volume resuscitation (2C)
Use of human albumin if necessary for the treatment of patients with septic shock (2C).
Use of diuretics
No loop diuretics for the prevention of AKI (Grade 1B)
Diuretics to control or avoid fluid overload in patients that are diuretic-responsive (Grade 2D)
Use of vasopressors
Titrating vasopressors to a MAP of 65–70 mmHg (Grade 1B) in patients with septic shock and to (80–85 mmHg) for
patients with chronic HTN (Grade 1C).
lowering SBP to 140–190 mmHg in patients with acute cerebral hemorrhage with severe admission hypertension (Grade
1C)
Norepinephrine as the first-choice vasopressor to protect kidney function (Grade 1B) and vasopressin in patients with
vasoplegic shock after cardiac surgery (Grade 2C).
Individualizing target pressure when premorbid blood pressure is available (BPS)
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12. Prognosis of acute kidney injury
With the advent of agreed definition and classification of AKI based on changes in serum
creatinine and urine output, there is now increasing awareness of the poor prognosis following
AKI. Multiple studies have shown that patients with AKI are at high risk for progression to
advanced stage CKD and death following hospital discharge. In a meta-analysis of 13 cohort
studies comparing the risk of CKD, ESRD, and death in patients with and without AKI, the
pooled incidence of CKD and ESRD were 25.8/100 person-years and 8.6/100 person-years,
respectively [8]. Patients with AKI had higher risks of developing CKD (pooled adjusted
hazard ratio 8.8), ESRD (pooled adjusted HR 3.1), and mortality (pooled adjusted HR 2.0) than
patients without AKI [8]. In another meta-analysis of 48 studies containing 47,107 patients
Use of vasodilators
No low-dose dopamine for protection against AKI (Grade 1A)
No levosimendan for renal protection in patients with sepsis and in cardiac surgery patients with poor preoperative left
ventricular function (Grade 1B).
No fenoldopam or natriuretic peptides for renal protection in critically ill or cardiovascular surgery patients at risk of AKI
(Grade 2B).
Sedatives
Shorter sedation using propofol or dexmedetomidine (BPS)
Hormonal manipulation
Target a blood glucose level of at least below 180 mg/dL (10 mmol/l) (Grade 2B).
Use of erythropoietin or steroids (Grade 2 B)
Metabolic interventions
Avoid using high-dose IV selenium for renal protection in critically ill patients (1B)
Avoid using N-acetylcysteine to prevent contrast-associated AKI in critically ill patients (Grade 2B)
Provide adequate nutritional support preferably through the enteral route (BPS)
Statins
Avoid the use of high-dose statins to prevent postoperative AKI in cardiac surgery (Grade 1A)
Use atorvastatin or rosuvastatin to prevent contrast-associated AKI in high-risk patients undergoing coronary contrast
angiography (Grade 2B)
Remote ischemic preconditioning
Do not use remote ischemic preconditioning for prevention of AKI in critically ill patients
AKI care bundles
Use of the KDIGO recommendations to reduce the incidence of AKI after cardiac surgery (Grade 2C).
Use of AKI care bundles outside the intensive care unit has some benefits, including the potential to improve the outcome
of AKI (BPS).
AKI, acute kidney injury; HTN, hypertension; MAP, mean arterial pressure; BPS, best practice statement.
Table 5. Expert opinion of theWorking Group on Prevention, AKI section, European Society of Intensive Care Medicine [125].
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between 1985 and 2007 the incidence rate of mortality was 8.9 deaths/100 person-years in
survivors of AKI compared to 4.3 deaths/100 patient-years in survivors without AKI (rate ratio
2.59) [126]. The incidence rate of CKD after an episode of AKI was 7.8 events/100 patient-years,
and the rate of ESRD was 4.9 events/100 patient-years [126]. In an observational cohort study
with a median follow-up of 9 years the intermediate-term (30–364 days) adjusted mortality
HRs for AKI versus no AKI were 2.48, 2.50, 1.90, and 1.63 for baseline eGFRs ≥60, 45–59, 30–44,
and <30 mL/min/1.73 m2, respectively [127]. This indicates that baseline renal function is an
important determinant factor for outcome following an episode of AKI. A retrospective cohort
study showed that patients who developed AKI during a hospitalization were at substantial
risk for the development of CKD in the following year, and the timing of recovery was a strong
predictor, even for the mildest forms of AKI [128].
The multinational AKI-EPI study on ICU patients in 97 centers showed that increasing AKI
severity was associated with increased mortality, and AKI patients had worse renal function at
the time of hospital discharge [16].
According to the United States Renal Data System, acute tubular necrosis (ATN) without
recovery as a cause of ESRD increased from 1.2% in 1994 to 1998 to 1.7% in 1999 to 2003 [129].
The incidence will likely continue to rise with the aging population and increase in
comorbidities in patients admitted to the ICU.
Risk factors associated with progressing to CKD among AKI survivors have been identified
and include advanced age, diabetes mellitus, decreased baseline glomerular filtration rate,
severity of AKI, and a low concentration of serum albumin [6, 130].
13. Conclusion
Acute kidney injury, previously named acute renal failure, is characterized by abrupt deterio-
ration in renal function. The incidence of AKI has lately increased, both in the hospital and
community setting. Management of AKI involves fluid resuscitation, avoidance of nephrotoxic
agents, adjustment of medications, and correction of fluid, acid-base and electrolyte imbalance.
Depending on the severity of renal insult, AKI may require renal replacement therapy in the
form of dialysis or continuous renal replacement. Despite all the advances in the field, AKI still
carries a high mortality and long term consequences. Recognition of risk factors, early diagno-
sis, and management of AKI are crucial to improve the long-term patient’s outcome.
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